ArticleEuropean journal of heart failure2025
Atrial cardiomyopathy: From healthy atria to atrial failure. A clinical consensus statement of the Heart Failure Association of the ESC.
Article in European journal of heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Understanding atrial failure: from diagnosis to clinical implications.Nature reviews. Cardiology · 2026Review
- Development of a Diagnostic Model Based on Serum ST2 and Left Atrial Strain for Left Ventricular Systolic Dysfunction in Patients With Chronic Coronary Syndrome.Echocardiography (Mount Kisco, N.Y.) · 2026Article
- Computational modeling identifies protective mechanisms of estrogen and testosterone against atrial fibrosis.American journal of physiology. Heart and circulatory physiology · 2026Article
- Electrical and Structural Atrial Remodeling Identifies a High-Risk Phenotype in Embolic Stroke of Undetermined Source.JACC. Advances · 2026Article
- Right ventricular to pulmonary artery coupling and clinical outcomes after interatrial shunting in heart failure: exploratory analysis of the PRELIEVE study.ESC heart failure · 2026Article
- Prognostic impact of chronotropic incompetence in transthyretin cardiac amyloidosis: a multicentre study.ESC heart failure · 2026Article
- Epigenetics in Atrial Fibrillation: Molecular Mechanisms and Therapeutic Avenues.Reviews in cardiovascular medicine · 2026Review
- Amplified P-wave duration predicts incident atrial fibrillation in the general population: Results from the Hamburg City Health Study.Heart rhythm O2 · 2026Article
- Perspectives on phenotype in genetic testing for early-onset atrial fibrillation.European journal of human genetics : EJHG · 2026Article
- Head-to-head comparison of non-invasive markers of atrial cardiomyopathy and their association with arrhythmia recurrence after atrial fibrillation ablation.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Atrial Cardiomyopathy and Atrial Fibrillation: Insight From Histopathological Analysis of Atrial Biopsies.Korean circulation journal · 2026Review
- Atrial Fibrillation in Infiltrative Cardiomyopathies: From Atrial Cardiomyopathy Imaging to Targeted Management-A Narrative Review.Medicina (Kaunas, Lithuania) · 2026Review
- Diagnostic uncertainties in older inpatients with suspected heart failure with preserved ejection fraction: a pilot cohort study.Internal and emergency medicine · 2026Article
- Stratifying prognosis in heart failure patients with reduced ejection fraction and atrial cardiomyopathy.ESC heart failure · 2026Article
- End-stage valvular heart disease requiring heart transplantation: risk profile, surgical modifiers, and myocardial pathology.BMC cardiovascular disorders · 2026Article
- Association of non-invasive atrial cardiomyopathy markers with cerebral stroke lesions: a population-based analysis from the Hamburg City Health Study.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026Article
- Role of imaging techniques in monitoring atrial cardiomyopathy and atrial failure: a scientific statement.ESC heart failure · 2026Review
- Atrial Cardiomyopathy.Maedica · 2026Article
- Emerging biomarkers for improved risk prediction of atrial fibrillation: potential role of bone morphogenic protein 10.American journal of physiology. Heart and circulatory physiology · 2026Article
- Atrial fibrillation increases left and right atrial pressures in patients with chronic heart diseases.ESC heart failure · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The importance of atrial cardiomyopathy (AtCM) as a specific clinical entity is increasingly recognized. Past definitions have varied, and the lack of consistent cut-offs for imaging parameters and biomarkers have limited clinical utility to diagnose and track AtCM progression. While research has mainly focused on AtCM in the context of atrial fibrillation, emerging evidence underscores its relevance in remodelling and development of heart failure. The aim of this consensus document was to provide a contemporary framework for AtCM, evolve the definitions of AtCM and atrial failure for more widespread clinical use, and help to direct emerging research and future clinical trials. Supporting the work of early career researchers, this consensus document evaluates diagnostic markers and summarizes the underpinning mechanisms, clinical characteristics and prognostic impact of AtCM. Our objective was to bring together new translational scientific progress, catalyse future research and enable clinical application to facilitate better management, for example in patient groups where aggressive control of risk factors or comorbidities could prevent AtCM progression. We redefined AtCM as a graded disorder that includes electrical dysfunction of the atria along with evidence of either mechanical atrial dysfunction, atrial enlargement and/or atrial fibrosis. Atrial failure is the end-stage manifestation of AtCM, characterized by progressive structural, electrophysiological and functional changes. Earlier identification, risk stratification and ongoing research into therapeutic options have the potential to prevent the clinical consequences of AtCM and atrial failure, including adverse patient outcomes and poor quality of life associated with atrial fibrillation and heart failure.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.